Cargando…
Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatment
BACKGROUND. Thrombotic events, arterial or venous in origin, still remain a source of substantial morbidity and mortality in cancer patients. The propensity for their development in oncology patients is partially a consequence of the disease itself and partially a result of our attempts to treat it....
Autores principales: | Perpar, Ana, Brecelj, Erik, Kozjek, Nada Rotovnik, Anderluh, Franc, Oblak, Irena, Vidmar, Marija Skoblar, Velenik, Vaneja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Versita, Warsaw
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387995/ https://www.ncbi.nlm.nih.gov/pubmed/26029030 http://dx.doi.org/10.2478/raon-2014-0024 |
Ejemplares similares
-
Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014) -
Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia
por: Jeromen, Ana, et al.
Publicado: (2012) -
Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial
por: Velenik, Vaneja, et al.
Publicado: (2012) -
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
por: Velenik, Vaneja, et al.
Publicado: (2011) -
Definitive Radiochemotherapy in Esophageal Cancer - A Single Institution Experience
por: Anderluh, Franc, et al.
Publicado: (2019)